Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Adolescents and Adults With Chronic Plaque Psoriasis
Public ClinicalTrials.gov record NCT04279119. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open Label, Phase 1, Maximal Usage Pharmacokinetics and Safety Study of ARQ-151 Cream 0.3% Administered QD in Adolescent and Adult Subjects With Chronic Plaque Psoriasis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a phase 1, open label, single arm study in which ARQ-151 cream 0.3% is applied QD for 2 weeks to adolescent subjects with chronic plaque psoriasis involving at least 10% body surface area (BSA) and adult subjects with chronic plaque psoriasis involving at least 20% BSA (excluding scalp). The objectives of this study are to evaluate the exposure and characterize the plasma pharmacokinetic profile and to assess the safety and tolerability of ARQ-151 cream 0.3% administered once daily for 2 weeks to adolescent and adult subjects with chronic plaque psoriasis.
Study identification
- NCT ID
- NCT04279119
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 26 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 9, 2020
- Primary completion
- Mar 24, 2021
- Completion
- Mar 24, 2021
- Last update posted
- Aug 2, 2022
2020 – 2021
United States locations
- U.S. sites
- 12
- U.S. states
- 7
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arcutis Clinical Site 09 | Rogers | Arkansas | 72758 | — |
| Arcutis Clinical Site 11 | Fountain Valley | California | 92708 | — |
| Arcutis Clinical Site 07 | Coral Gables | Florida | 33134 | — |
| Arcutis Clinical Site 03 | Doral | Florida | 33122 | — |
| Arcutis Clinical Site 06 | Hialeah | Florida | 33016 | — |
| Arcutis Clinical Site 12 | Miami | Florida | 33144 | — |
| Arcutis Clinical Site 04 | Sanford | Florida | 32771 | — |
| Arcutis Clinical Site 02 | Plainfield | Indiana | 46168 | — |
| Arcutis Clinical Site 01 | Dublin | Ohio | 43016 | — |
| Arcutis Clinical Site 10 | Arlington | Texas | 76011 | — |
| Arcutis Clinical Site 05 | San Antonio | Texas | 78213 | — |
| Arcutis Clinical Site 08 | Richmond | Virginia | 23226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04279119, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 2, 2022 · Synced Sep 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04279119 live on ClinicalTrials.gov.